All In Biotech

NDA 211810 · Daiichi Sankyo INC

Turalio

Pexidartinib Hydrochloride · Oral

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Aug 27, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Aug 2, 2019

Approved uses

3

Original approval plus efficacy supplements

Registered trials

29

2 Phase 3, 2 recruiting

FAERS reports

717

117 serious, 14 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HEPATOTOXICITY TURALIO can cause serious and potentially fatal liver injury, including vanishing bile duct syndrome [see Warnings and Precautions (5.1) ] . Monitor liver tests prior to initiation of TURALIO and at specified intervals during treatment. Withhold and dose reduce or permanently discontinue TURALIO based on severity of hepatotoxicity. Monitoring and prompt cessation of TURALIO may not eliminate the risk of serious and potentially fatal liver injury [see Dosage and Administration (2.2) , Warnings and Precautions (5.1) ] . TURALIO is available only through a restricted program called the TURALIO Risk Evaluation and Mitigation Strategy (REMS) Program [see Warnings and Precautions (5.2) ] . WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. TURALIO can cause serious and potentially fatal liver injury, including vanishing bile duct...

What it is approved for

From the label in effect Jan 16, 2025.

TURALIO is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. TURALIO is a kinase inhibitor indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. ( 1 )

Mechanism: Pexidartinib is a small molecule tyrosine kinase inhibitor that targets colony stimulating factor 1 receptor (CSF1R), KIT proto-oncogene receptor tyrosine kinase (KIT), and FMS-like tyrosine kinase 3 (FLT3) harboring an internal tandem duplication (ITD) mutation. Overexpression of the CSF1R ligand promotes cell proliferation and accumulation in the synovium. In vitro, pexidartinib inhibited proliferation of cell lines dependent on CSF1R and ligand-induced autophosphorylation of CSF1R. Pexidartinib also inhibited the proliferation of a CSF1R dependent cell line in vivo.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 14, 2022 Supplement 9 · Efficacy OrphanLetterLabel
  • Oct 6, 2022 Supplement 8 · Efficacy OrphanLetter
  • Aug 2, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
2 products under this application
  • TURALIO · PEXIDARTINIB HYDROCHLORIDE EQ 125MG BASE · CAPSULE, ORAL · Prescription
  • TURALIO · PEXIDARTINIB HYDROCHLORIDE EQ 200MG BASE · CAPSULE, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Pexidartinib" as an intervention, any sponsor and status, largest first.

All 29 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product dose omission issue270
  • fatigue251
  • hair colour changes236
  • nausea138
  • pruritus113
  • off label use106
  • rash87
  • therapy cessation81
  • pain76
  • headache72
  • product dose omission in error69
  • product use issue67

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201937
2020109
2021131
2022115
2023120
2024105
202561
202639

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Turalio (Pexidartinib Hydrochloride)

2024 spending

$2.4M

Beneficiaries

19

145 claims

Per beneficiary

$125,826

$188.99 per unit

View as table
YearSpending
2020$916,537
2021$709,881
2022$1,148,375
2023$1,798,156
2024$2,390,695

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 18 on PubMed

Sponsor: Daiichi Sankyo

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.